ZERO-MIGRAINE DAYS ARE POSSIBLE

A SIMPLE ONCE-DAILY PILL


Quick and Continuous reductions that last1

 

Across 12 weeks, QULIPTA® 60 mg reduced attacks for both episodic and chronic migraine patients.1

EM primary endpoint: Significant -4.2 monthly migraine day reduction from 7.8 baseline (n=222; P<0.001) vs -2.5 from 7.5 baseline for placebo (n=214)1

CM primary endpoint: Significant -6.9 monthly migraine day reduction from 19.2 baseline (n=256; P<0.001) vs -5.1 from 18.9 baseline for placebo
(n=246)1

NOW APPROVED FOR CHRONIC MIGRAINE

*Specific to episodic migraine.

Managed Markets Insight & Technology, LLC™, a trademark of MMIT. Data as of August 2024 and subject to change.

Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits are determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. AbbVie does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.

Data from Phase 3 ADVANCE EM pivotal study.

§Data from Phase 3 PROGRESS CM pivotal study.

Data from 52-week, open-label, long term safety study for EM.

CM=chronic migraine; EM=episodic migraine.